Israel’s BioSight has announced positive results of the Phase 1/2 study of its lead product BST-236, a novel cytarabine pro-drug, as a single agent for induction therapy in acute leukemia patients. It was effective on many patients who had failed with previous standard therapy.

https://finance.yahoo.com/news/biosight-announces-phase-ii-results-135600604.html